Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Posts Increased Revenue, Widened Loss in Q4

NEW YORK, Feb. 5 - Cepheid on Tuesday posted increased revenues and a significantly widened loss for the fourth quarter 2001.

 

For the three months ended Dec. 31, the company reported revenues of $3.2 million, compared with $2.6 million in the same period one year ago. Cepheid said the increase was due to a jump in sales of its Smart Cycler DNA analysis systems: the company said it sold $2.9 million of the units in the fourth quarter of 2001 compared with $1.8 million in the year-ago period.

 

Cepheid also said that net losses widened to $4.2 million, or $.16 a share in the fourth quarter of 2001, compared with $3.2 million, or $.12 a share one year ago. R&D spending increased roughly $470,000 year-over-year to nearly $4 million.

 

Cepheid said it has roughly $25.3 million in the bank and plans to burn an average of $1.5 million a month during the new year.

 

Its outlook for the first three months of 2002 calls for product sales to remain flat at between $2.5 million and $2.9 million, and for its per-share net loss to grow to between $.19 and $.20.

 

Shares in the Sunnyvale, Calif.-based company dipped $.16, or nearly 5 percent, to close at $3.06 in Nasdaq trading on Tuesday.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.